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Introduction 52
Antibiotic use is a primary driver of antibiotic resistance, and reducing antibiotic use is a central 53 strategy for combatting resistance (1, 2) . Understanding the relationship between antibiotic use 54 and antibiotic resistance is therefore critical for the design of rational antibiotic stewardship 55 strategies. Multiple studies have identified cross-sectional relationships between antibiotic use 56 and resistance, especially across European countries and US states (3-9). In general, these 57 studies compare total outpatient antibiotic use with population-level resistance. However, 58 antibiotic use is generally not evenly distributed. A study of outpatient prescribing in the UK 59 found that 30% of patients were prescribed at least one antibiotic per year, with the top 9% of 60 patients receiving 53% of all antibiotics (10). A study of beneficiaries of Medicare, a national 61 health insurance program that covers that vast majority of Americans 65 and older, found that the 62 proportion of beneficiaries who take antibiotics varies by US state and drug class (11). In some 63 cases, antibiotic courses can last for months or even years (12, 13) . Because antibiotic use is 64 uneven, total use does not distinguish between broad use-many people receiving a few 65 prescriptions-and intense use-a few people receiving many prescriptions (14) . 66 67 It stands to reason that the distribution of antibiotic use, not just total use, could have an effect on 68 resistance (15). There are a few studies of the relationship between repeated antibiotic exposure 69 on antibiotic resistance (16-22), and it remains unclear whether broad use or intense use is 70 associated with population-level resistance. For example, if a first course of antibiotics given to 71 an antibiotic-naive patient clears most of the susceptible bacteria they carry, then a second course 72 in the same patient will have only a small effect, since most susceptible bacteria were already 73 eliminated. Giving that second course to a different, antibiotic-naive patient instead would have a 74 greater effect on population-level resistance. On the other hand, multiple courses given to a 75 single patient might have a synergistic effect on resistance. 76
77
The goal of this study was to test the hypothesis that intense antibiotic use has a stronger 78 association with population-level resistance than broad, low-level antibiotic use. We used an 79 ecological design to compare the distribution of antibiotic use with antibiotic resistance. 80
Although an ecological design is potentially subject to confounders and cannot definitively test 81 for the causal effect of the distribution of use on resistance at the individual level, ecological 82 studies of use and resistance are the most feasible design for studying the relationship between 83 antibiotic use and population-level resistance, and the results of ecological designs play an 84 important role in developing antibiotic stewardship policies (23, 24) . 85
86
To test this hypothesis, we first characterized the distribution of outpatient antibiotic use in two 87
US nationwide pharmacy prescription claims databases, Truven Health MarketScan Research 88
Database (25) and Medicare, both covering 2011-2014. We considered only outpatient antibiotic 89 prescribing, which accounts for 80-90% of total medical antibiotic use in the UK and Sweden 90 (26, 27) and is presumed to account for a similar fraction in the US (28). Unlike antibiotic sales 91 data and nationwide healthcare surveys (29), MarketScan and Medicare claims data, which have 92 previously been used to characterize variations in antibiotic use (11, 30-32), provide longitudinal 93 prescribing information about individual people, which can distinguish between many people 94 getting a few prescriptions and a few people getting many prescriptions. We characterized the 95 distribution of antibiotic use across US states by partitioning annual total use as the sum of 96 annual first use-individuals' first pharmacy fill for an antibiotic in a calendar year-and annual 97 repeat use-pharmacy fills beyond individuals' first ones in a calendar year. Second, we 98 compared annual total antibiotic use with antibiotic resistance as measured in ResistanceOpen, a 99 US nationwide sample of antibiotic susceptibility reports, for 2012-2015 (i.e., lagged by one year 100 (8, 33)), evaluating the relationship between use and resistance across US states for 72 pathogen-101 antibiotic combinations. Finally, we evaluated whether annual first use and annual repeat use are 102 differently associated with population-level resistance. Table 1 ). For all 113 drug groups, most people had zero prescriptions for that antibiotic in a given year, but antibiotics 114 differed in their distributions ( Figure 1 ). 115
116
We next examined the distribution of antibiotic use for each drug group and US state. To 117 quantify the distribution of antibiotic use, we labeled each antibiotic pharmacy claim as "first" if 118 it was the first pharmacy fill for that drug group made by that individual in that calendar year, 119 and "repeat" if it was a second, third, etc. fill for an antibiotic in the same drug group made by 120 the same individual in the same calendar year. An individual's first and repeat claims in a 121 calendar year add up to their total number of claims for that year. We then partitioned 122 population-level annual total use, measured as pharmacy fills per 1,000 members per year, into 123 the sum of annual first use, measured as first fills per 1,000 members per year, and repeat use, 124 measured as repeat fill per 1,000 members per year, for each drug group and US state. Annual 125 first use of a drug group is equivalent to the proportion of the population taking an antibiotic in 126 that group in that year. 
Landscape of correlations between total use and resistance across pathogens and antibiotics 139
To verify that our antibiotic use and resistance data sources could be used to distinguish the 140 associations of first use and repeat use with antibiotic resistance, we first measured the landscape 141 of Spearman correlations between total use and antibiotic resistance for multiple pathogens and 142 antibiotics (3-8). To measure antibiotic resistance, we used a US nationwide sample of hospital 143 antibiotic susceptibility reports (35), which included resistance of 38 pathogens to 37 antibiotics 144 in 641 antibiotic susceptibility reports from 230 organizations (hospitals, laboratories, and 145 surveillance units) spread over 44 US states. Although most organizations contributing antibiotic 146 susceptibility reports were hospitals, hospital antibiotic susceptibility reports are biased toward 147 community-acquired organisms (36, 37), and studies often compare hospital antibiotic 148 susceptibility reports with community antibiotic use (38). 149 150 Because the epidemiology and pharmacology of each pathogen-antibiotic combination is unique, 151 each combination could have a unique use-resistance relationship (15). We therefore aggregated 152 antibiotic resistance into the same drug groups with which we aggregated antibiotic use 153 (Supplementary File 1 - Table 1 ) and evaluated the 72 pathogen-antibiotic combinations that 154 were adequately represented in the antibiotic resistance data (see Methods). Across those 72 155 combinations, correlation coefficients ranged from -32% to 64% (Figure 3 , Supplementary File 156 1 - Table 2 ). The strongest correlation (Spearman's ρ = 64%, 95% CI 41 to 80%) was between 157 macrolide use and the proportion of Streptococcus pneumoniae isolates that were macrolide 158 nonsusceptible ( Figure 4 ). Correlation coefficients were mostly positive (median correlation 159 coefficient 21%, IQR 8 to 34%). Use-resistance correlations involving macrolides, quinolones, 160 and cephalosporins were more positive than those for nitrofurantoin, and correlations involving 161 quinolones were more positive than those for trimethoprim/sulfamethoxazole (pairwise Mann-162 Whitney tests, two-tailed, FDR = 0.05). Coefficients were not significantly more positive for any 163 particular pathogen. File - Tables 2 and 3) . Thus, the landscape of correlations we observed was mostly robust to the 176 exact population and data source. 177
178
We also evaluated the sensitivity of the results to the measurement of antibiotic use, substituting 179 days supply of antibiotic for number of pharmacy fills, and the geographic level of the analysis, 180 by aggregating the Medicare use data and resistance data at the level of the 306 hospital referral 181 regions intended to approximate regional health care markets (41) (Supplementary File -Tables 182 2 and 3). The absolute values of the correlation coefficients were slightly closer to zero when 183 using days supply rather than fills (Wilcoxon test, two-tailed; pseudomedian difference in 184 absolute correlation coefficient 1.9 percentage points, 95% CI 0.72 to 3.1) and substantially 185 closer to zero when using hospital referral regions rather than states as the units of analysis (6.1 186 percentage points, 95% CI 3.0 to 9.1). 187
188 Lack of evidence for more positive association with repeat use 189
Having examined the landscape of the relationships between total use and resistance across 190 pathogen-antibiotic combinations, we set out to test the hypothesis that repeat use has a stronger 191 association with resistance than first use. For each pathogen-antibiotic combination, we 192 performed a multiple regression predicting proportion nonsusceptible from first use and repeat 193 use ( Figure 5 ). First use and repeat use are highly correlated in some cases (Supplementary File -194 - Table 4 ) which will widen the confidence intervals on the regression coefficients but should not 195 introduce bias (42). Regression coefficients for first use were more often positive than negative 196 (54 of 72 [75%]; binomial test, 95% CI 63 to 84%). That is, first use was positively associated 197 with resistance when controlling for repeat use. In contrast, regression coefficients for repeat use 198 were more often negative than positive (44 of 72 [61%]; binomial test, 95% CI 49 to 72%). That 199 is, repeat use was negatively associated with resistance when controlling for first use. 200
201
We evaluated the sensitivity of this result to age group, data source, metric of antibiotic use, and 202 geographic unit of analysis, as described above. In all cases, regression coefficients for first use 203 in the multiple regression were more likely to be positive than negative, while regression 204 coefficients for repeat use were more likely to be negative than positive (Supplementary File 1 -205 Table 5 ). For certain pathogens and antibiotics, resistance could presumably accumulate in an 206 individual over many years (18, 21), so we also computed alternate measures of first and repeat 207 use by considering only individuals who were included in the MarketScan data for each year of 208 2011-2014, and we labeled an antibiotic fill as first use only if it was the first fill for that drug 209 group made by that individual in the entire four-year period. In that analysis, a similar proportion 210 of regression coefficients for first use were positive (69%, 95% CI 57 to 80%) and regression 211 coefficients for repeat use were equally likely to be positive or negative (53%, 95% CI 41 to 212 65%). 213 214 Discussion 215
Landscape of use-resistance relationships 216
We used US nationwide datasets measuring antibiotic use in 60 million individual and antibiotic 217 resistance in 3 million bacterial isolates to analyze relationships between antibiotic use and 218 resistance, examining 72 pathogen-antibiotic combinations simultaneously, using identical data 219 sources and analytical methods across combinations. Although previous studies have examined 220 multiple pathogen-antibiotic combinations, usually no more than 5 pathogens or antibiotics are 221 considered at once (3, 4, 8). We found that correlations between total use and resistance were 222 mostly positive, that certain drugs tended to have more positive correlations, but that there was 223 no clear pattern by organism (6). The overall landscape of correlations was mostly robust to the 224 age groups studied and the geographic scale of the analysis, although correlations were 225 somewhat weaker when conducting analysis at smaller geographic scales (8, 43-45). We used 226 outpatient antibiotic use as the predictor of resistance because 80-90% of antibiotic use occurs in 227 the outpatient setting (28) and because most antibiotic pressure on pathogens is due to "bystander 228 selection", in which the patient is treated for some reason other than an infection caused by that 229 pathogen (46). 230
231
The correlations we observed between total antibiotic use and population-wide antibiotic 232 resistance were noticeably weaker than those in highly cited European studies but comparable to 233 those from other analyses of European data. For example, for S. pneumoniae and macrolides, 234 relation (-11%, 95% CI -41 to 22%). We propose that the narrow variation in β-lactam use 245 across US states, approximately two-fold between the highest-and lowest-using states, obscures 246 a correlation that is more apparent in Europe, where there is a four-fold variation between the 247 highest-and lowest-using countries (3). Thus, our results and those from Goossens et al. may be 248 consistent with respect to the underlying biology. We also note that, when reproducing the 249 methodology from a US study (47) of the use-resistance relationship for β-lactams and S. 250 pneumoniae (dichotomizing states as high-or low-prescribing and computing the odds ratio of 251 resistance), we find a consistent point estimate but with wider confidence intervals (1.15, 95% CI 252 0.75 to 1.76). 253 254 Our study design may limit the interpretability of the landscape of use-resistance relationships. 255
First, like the leading European studies using EARS-Net and US studies using the Centers for 256
Disease Control and Prevention Active Bacterial Core surveillance, we compare population-wide 257 outpatient antibiotic use with antibiotic susceptibility reports from hospitals. The degree to which 258 hospital antibiotic susceptibility reports represent community infections is debated (36, 38). For 259 example, if outpatient antibiotic use selects for resistance among community-acquired infections, 260 and hospital antibiograms reflect data from community-acquired infections as well as unrelated 261 inpatient resistance patterns, then the correlations we measure would be biased toward weaker 262 associations. Furthermore, antibiotic use and resistance in the community setting is not 263 completely independent of use and resistance in the hospital setting (48), and our approach does 264 not account for any relationship between the two. 265 266 Second, antibiotic resistance is temporally dynamic, and our cross-sectional approach assumes 267 that antibiotic use is autocorrelated across years (49) or resistance changes slowly (50). If use 268 does cause resistance, and use and resistance changed meaningfully over the course of the study, 269 then the correlations we measured by aggregating over all years would be biased toward weaker 270 associations. 271 272 Third, because of the limitations in statistical power, we did not address the possibility that use 273 of one antibiotic can select for resistance to another antibiotic (51, 52). Notably, use of one 274 antibiotic can select for resistance to another antibiotic if the dominant clones of that species are 275 resistant to both (51). In that case, if the use rates of the two drugs are correlated across states, 276 then the apparent relationship between one drug and resistance to that drug would be biased 277 upward. Furthermore, because the palette of antibiotic use varies by country (53), and different 278 pathogen strains circulate in different populations, the univariate associations we observed 279 between use of an antibiotic and resistance to that antibiotic in the US may not be applicable in 280 other geographies. 281 282 Finally, like in other studies of antibiotic use, we did not address patient adherence, and typical 283 approaches to address adherence using claims data (54) are problematic when the intended 284 duration of treatment is not clear. The measured correlation would then be biased if, for example, 285 poor patient adherence increased resistance and patient adherence were correlated with antibiotic 286 use. 287 288
Distribution of antibiotic use and antibiotic resistance 289
We described the distribution of antibiotic use across drug groups and US states, finding that 290 34% of the study population took an antibiotic in a year, and 10% of the population had 57% of 291 the antibiotic fills in that year, similar to results from the UK (10), although this distribution 292 varied by population ( Figure 1 -Figure Supplement 1 ). By partitioning annual total use into 293 annual first use and annual repeat use, we were able to show that, for each drug, annual first use 294 makes up the majority of annual total use and that variations in annual first use explain more 295 variance in annual total use than do variations in annual repeat use. We also found that first use 296 tends to have a positive association with resistance when controlling for repeat use, while repeat 297 use tends to have negative or associations with resistance when controlling for first use. This 298 result held across sensitivity analyses. 299 300 If these associations are causal, that is, if outpatient first and repeat antibiotic use select for 301 resistance among community-acquired pathogens, then our results would imply that antibiotic 302 resistance in the outpatient setting is due more to first use, which tended to have positive 303 associations with resistance, than to repeat use. In contrast to proposals to focus on intense 304 antibiotic users for combatting resistance (10), this situation would imply that preventing 305 marginal prescriptions among patients whose indications are borderline-appropriate or 306 inappropriate for antibiotics may be the more effective tactic for reducing the prevalence of 307 resistance mechanisms already established in the US. 308
309
There are limitations to the interpretability of these results. First, as mentioned above, there is a 310 potential mismatch between the sources of the antibiotic use and antibiotic resistance data. 311 312 Second, although antibiotic use is a major driver of antibiotic resistance, the observed results 313 may not be causal. Factors beyond antibiotic use, like population density, play a role in antibiotic 314 resistance (2, 9). Even if antibiotic use and resistance are causally related, it may be that 315 resistance affects antibiotic use. For example, if resistance to a drug is high, treatment using that 316 drug is more likely to fail, discouraging repeated use, so that high resistance lead to decreased 317 repeat use (36, 43, 51). Ecological studies like this one do not directly address causality, and 318 further work is needed to distinguish between different causal pathways. 319 320 Third, the observed population-level relationships between antibiotic use and resistance need not 321 also hold for the relationship between an individual's first and repeat antibiotic use and the risk 322 of a resistant infection in that individual. Any comparisons between our population-level results 323 and individual-level studies would need to account for the difference between our population-324 level measures of first and repeat antibiotic use and the individual-level timing of antibiotic use 325 and measurements of resistance. 326 327 Fourth, controlling for factors beyond antibiotic use could alter the apparent relationship between 328 antibiotic use and resistance. In particular, we speculate that controlling for patient morbidity, 329 which we did not address in this population-level analysis, would amplify the observed result, 330 that first use tends to have a more positive association with antibiotic resistance than repeat use. 331
We expect that morbid individuals have more repeat antibiotic use. We also expect that morbid 332 individuals visit the hospital more often, putting them at higher risk of antibiotic resistant 333 infections regardless of their antibiotic use. Thus, we speculate that repeat use causes resistance 334 and also is a predictor of morbidity, which is associated with resistance. Failing to control for 335 morbidity thus biases the association between repeat use and resistance toward more positive 336 values. Conversely, controlling for morbidity would decrease the measured relationships 337 between repeat use and resistance, amplifying our central result. 338 339 Fifth, we defined first and repeat use with respect to the calendar year, while it may be that some 340 other timescale is the appropriate one for this analysis. Although our central result held when re-341 defining first and repeat use with respect to a four-year period (Supplementary File 1 - Table 5) , 342 it may be that, say, repeat use within an individual on a time-scale shorter than a year is an 343 important determinant for risk of resistance in that individual. Our study does not distinguish 344 between repeat use that occurs across year boundaries, which is presumably important for 345 relating individuals' antibiotic use with their risk of resistance. 346 347 Finally, we note that first use and repeat use are only one set of many ways of measuring the 348 distribution of antibiotic use. For example, 10 repeat uses could mean 1 person with 10 repeat 349 uses or 10 people with 1 repeat use each. The first and repeat use metrics cannot distinguish 350 between these two cases, and it may be that some other measure of the distribution of antibiotic 351 use would yield different results. 352
353
In conclusion, we find that population-wide antibiotic use and population-wide resistance 354 appears to be more closely linked with broadly-distributed, low-intensity use rather than with 355 intensity of use. Ultimately, accurate models predicting the emergence and spread of antibiotic 356 resistance will require more careful characterizations of who gets what antibiotic (55) data, only members who were on their insurance plan for 12 months during a given year were 372 included. Prescription fills for oral and injected antibiotics were identified by generic 373 formulation (Supplementary File 1 - Table 6 ) and drug forms (Supplementary File 1 - Table 7) . 374
We treated multiple fills on the same day for the same generic formulation with the same refill 375 code as a single prescription fill. In the main analysis, antibiotic use was measured using fills, 376 rather than days supply of drug, because some previous research has suggested that prescriptions 377 better correlate with resistance (33) and that this choice is probably not detrimental (8, 49). The 378 specific generic drugs were grouped into antibiotic drug groups designed to correspond to the 379 antibiotic resistance drug groups described below (Supplementary File 1 - Table 1 ). All measures 380 of antibiotic use were computed for each year 2011 to 2014, and the mean for each value across 381 the 4 years was reported and used in analyses of the use-resistance relationship. 382 383 Antibiotic use among Medicare beneficiaries was measured as previously described (59). 384
Briefly, we considered fee-for-service beneficiaries at least 65 years old among and with 12 385 approximately 86,000 records, each indicating the fraction of isolates of an organism that were 399 nonsusceptible to a particular drug in a particular antibiotic susceptibility report ("antibiogram"). 400
The median number of isolates corresponding to each record was 93, but records had up to 401 75,000 associated isolates. 7 records (<0.01%) with missing numbers of isolates were excluded. 402
In antibiograms that separated S. aureus into MRSA and MSSA, resistance of aggregate S. 403 aureus to individual drugs was taken as the average of the MRSA and MSSA records, weighted 404 by number of isolates. MRSA and MSSA were not considered as separate species in any 405 analysis. 406
407
The specific antibiotics used in antibiotic resistance assays were grouped into antibiotic drug 408 groups (Supplementary File 1 - Table 1 ) designed to correspond to the antibiotic use groups. If 409 resistance to more than one antibiotic in a drug group was reported for a particular pathogen in a 410 particular antibiogram, resistance to that drug group for that pathogen in that antibiogram was 411 computed as the mean of the resistances measured for the antibiotics in 
